159 related articles for article (PubMed ID: 16171783)
1. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.
Rodríguez-Antona C; Sayi JG; Gustafsson LL; Bertilsson L; Ingelman-Sundberg M
Biochem Biophys Res Commun; 2005 Dec; 338(1):299-305. PubMed ID: 16171783
[TBL] [Abstract][Full Text] [Related]
2. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
3. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.
Mirghani RA; Sayi J; Aklillu E; Allqvist A; Jande M; Wennerholm A; Eriksen J; Herben VM; Jones BC; Gustafsson LL; Bertilsson L
Pharmacogenet Genomics; 2006 Sep; 16(9):637-45. PubMed ID: 16906018
[TBL] [Abstract][Full Text] [Related]
4. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
[TBL] [Abstract][Full Text] [Related]
5. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
Lamba JK; Lin YS; Thummel K; Daly A; Watkins PB; Strom S; Zhang J; Schuetz EG
Pharmacogenetics; 2002 Mar; 12(2):121-32. PubMed ID: 11875366
[TBL] [Abstract][Full Text] [Related]
6. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
8. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
9. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M
Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940
[TBL] [Abstract][Full Text] [Related]
10. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
[TBL] [Abstract][Full Text] [Related]
11. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
[TBL] [Abstract][Full Text] [Related]
12. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Gervasini G; García-Martín E; Ladero JM; Pizarro R; Sastre J; Martínez C; García M; Diaz-Rubio M; Agúndez JA
BMC Cancer; 2007 Jul; 7():118. PubMed ID: 17605821
[TBL] [Abstract][Full Text] [Related]
13. CYP3A phenotypes and genotypes in North Indians.
Rais N; Chawla YK; Kohli KK
Eur J Clin Pharmacol; 2006 Jun; 62(6):417-22. PubMed ID: 16758258
[TBL] [Abstract][Full Text] [Related]
14. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
Lee SJ; Goldstein JA
Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
[TBL] [Abstract][Full Text] [Related]
15. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
Cvetković M; Zivković M; Bundalo M; Gojković I; Spasojević-Dimitrijeva B; Stanković A; Kostić M
Ther Drug Monit; 2017 Dec; 39(6):589-595. PubMed ID: 29135906
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
[TBL] [Abstract][Full Text] [Related]
17. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.
Mirghani RA; Ericsson O; Tybring G; Gustafsson LL; Bertilsson L
Eur J Clin Pharmacol; 2003 May; 59(1):23-8. PubMed ID: 12743670
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
19. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.
Kolwankar D; Vuppalanchi R; Ethell B; Jones DR; Wrighton SA; Hall SD; Chalasani N
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):388-93. PubMed ID: 17368239
[TBL] [Abstract][Full Text] [Related]
20. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes.
Schirmer M; Rosenberger A; Klein K; Kulle B; Toliat MR; Nürnberg P; Zanger UM; Wojnowski L
Pharmacogenomics; 2007 May; 8(5):443-53. PubMed ID: 17465708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
